Intracellular delivery of protein and peptide therapeutics

Drug Discovery Today: Technologies

Volumn 5, Issue 2-3, 2008, Pages

  Torchilin, Vladimir ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA MANNOSIDASE; ASPARAGINASE; BETA FRUCTOFURANOSIDASE; BETA GALACTOSIDASE; BETA GLUCURONIDASE; CATALASE; CELL PENETRATING PEPTIDE; CYTOCHROME C OXIDASE; DEXTRANASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE 6 PHOSPHATE; GLUCOSE OXIDASE; GLUCOSYLCERAMIDASE; GLUTAMATE DEHYDROGENASE; HEAT SHOCK PROTEIN 70; HEXOKINASE; I KAPPA B ALPHA; LIPOSOME; MACROGOL; OXIDOREDUCTASE; PEPTIDE; PEROXIDASE; POLY(N ISOPROPYLACRYLAMIDE); PROTEIN; PROTEIN BCL XL; SIALIDASE; SUPEROXIDE DISMUTASE; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG;

BRAIN INFARCTION; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; ENDOSOME; INTRACELLULAR TRANSPORT; NONHUMAN; PH; REVIEW;

EID: 71849100518     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2009.01.002     Document Type: Review

References (86)

1. Wolf M., and Ransberger K. Enzyme-therapy (1972), Vantage Press
2. In: Holcenberg J.S., and Roberts J. (Eds). Enzymes as Drugs (1981), Wiley
3. In: Torchilin V.P. (Ed). Immobilized Enzymes in Medicine (1991), Springer-Verlag
4. In: Tager J.M., et al. (Ed). Enzyme Therapy in Lysosomal Storage Diseases (1974), North/Holland
5. Grabowsky G.A., and Desnick R.J. Enzyme replacement in genetic diseases. In: Holcenberg J.S., and Roberts J. (Eds). Enzymes as Drugs (1981), John Wiley 167
6. Froidevaux S., and Eberle A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66 (2002) 161-183
7. Figg W.D., et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs 20 (2002) 183-194
8. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2 (2002) 727-739
9. Ballard C.E., et al. Recent developments in depsipeptide research. Curr. Med. Chem. 9 (2002) 471-498
10. Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12 Suppl. 1 (2001) S35-S41
11. Harries M., and Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer. 9 (2002) 75-85
12. Marshall H. Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma. Trends Immunol. 22 (2001) 183-184
13. Varga C.M., et al. Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol. Bioeng. 70 (2000) 593-605
14. Chakrabarti R., et al. Transfer of monoclonal antibodies into mammalian cells by electroporation. J. Biol. Chem. 264 (1989) 15494-15500
15. Arnheiter H., and Haller O. Antiviral sTATe against influenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins. EMBO J. 7 (1988) 1315-1320
16. Straubinger R.M., et al. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 179 (1985) 148-154
17. Lasic D.D. Liposomes: From Physics to Applications (1993), Elsevier
18. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
19. Allen T.M., et al. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev. 16 (1995) 267-284
20. Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 123-193
21. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2 (1985) 65-115
22. In: Lasic D.D., and Martin F.J. (Eds). Stealth Liposomes (1995), CRC Press
23. Torchilin V.P., et al. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1279 (1996) 75-83
24. Torchilin V.P., et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511 (2001) 397-411
25. Torchilin V.P. Liposomal delivery of protein and peptide drugs. In: Mahato R.I. (Ed). Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press 433-459
26. Desnick R.J., et al. Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56 (1976) 57-99
27. Gregoriadis G. Liposomes in the therapy of lysosomal storage diseases. Nature 275 (1978) 695-696
28. Gregoriadis G., and Dean M.F. Enzyme therapy in genetic diseases. Nature 278 (1979) 603-604
29. Gregoriadis G., and Ryman B.E. Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats. Biochem. J. 129 (1972) 123-133
30. Steger L.D., and Desnick R.J. Enzyme therapy. VI: comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim. Biophys. Acta 464 (1977) 530-546
31. Reynolds G.C., et al. Enzyme replacement using liposome carriers in feline Gm1 gangliosidosis fibroblasts. Nature 275 (1978) 754-755
32. Das P.K., et al. Lectin-specific targeting of beta-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem. Med. 33 (1985) 124-131
33. Umezawa F., et al. Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher). Biochem. Biophys. Res. Commun. 127 (1985) 663-667
34. Yagi N., et al. Incorporation of enzyme into the brain by means of liposomes of novel composition. J. Appl. Biochem. 4 (1982) 121-125
35. Naoi M., and Yagi K. Incorporation of enzyme through blood-brainbarrier into the brain by means of liposomes. Biochem. Int. 1 (1980) 591-596
36. Torchilin V.P., et al. pH-Sensitive liposomes. J. Liposome Res. 3 (1993) 201-255
37. Sheff D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 56 (2004) 927-930
38. Asokan A., and Cho M.J. Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim. Biophys. Acta 1611 (2003) 151-160
39. Shalaev E.Y., and Steponkus P.L. Phase diagram of 1.2-dioleoylphosphatidylethanolamine (DOPE):water system at subzero temperatures and at low water contents. Biochim. Biophys. Acta 1419 (1999) 229-247
40. Simoes S., et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 56 (2004) 947-965
41. Fattal E., et al. 'Smart' delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv. Drug Deliv. Rev. 56 (2004) 931-946
42. Shigeta K., et al. Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J. Control. Release 118 (2007) 262-270
43. Sudimack J.J., et al. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta 1564 (2002) 31-37
44. Roux E., et al. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J. Control. Release 94 (2004) 447-451
45. Turk M.J., et al. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559 (2002) 56-68
46. Kakudo T., et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43 (2004) 5618-5628
47. Shi G., et al. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Release 80 (2002) 309-319
48. Geisert Jr. E.E., et al. Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci. Lett. 184 (1995) 40-43
49. Yessine M.A., and Leroux J.C. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv. Drug Deliv. Rev. 56 (2004) 999-1021
50. Chen G., and Hoffman A.S. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature 373 (1995) 49-52
51. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988) 1179-1188
52. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
53. Joliot A., et al. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U S A 88 (1991) 1864-1868
54. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88 (1997) 223-233
55. Schwarze S.R., and Dowdy S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21 (2000) 45-48
56. Lindgren M., et al. Cell-penetrating peptides. Trends Pharmacol. Sci. 21 (2000) 99-103
57. Hallbrink M., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 1515 (2001) 101-109
58. Zaro J.L., and Shen W.C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun. 307 (2003) 241-247
59. Wadia J.S., et al. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
60. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57 (2005) 579-596
61. Rothbard J.B., et al. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Deliv. Rev. 57 (2005) 495-504
62. Fawell S., et al. TAT-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U S A 91 (1994) 664-668
63. Moy P., et al. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol. Biotechnol. 6 (1996) 105-113
64. Kim D.T., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159 (1997) 1666-1668
65. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
66. Vocero-Akbani A., et al. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol. 322 (2000) 508-521
67. Becker-Hapak M., et al. TAT-mediated protein transduction into mammalian cells. Methods 24 (2001) 247-256
68. Nagahara H., et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
69. Embury J., et al. Proteins linked to a protein transduction domain efficiently transduce pancreatic islets. Diabetes 50 (2001) 1706-1713
70. Dolgilevich S., et al. Transduction of TAT fusion proteins into osteoclasts and osteoblasts. Biochem. Biophys. Res. Commun. 299 (2002) 505-509
71. Kwon H.Y., et al. Transduction of Cu, Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett. 485 (2000) 163-167
72. Jin L.H., et al. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic. Biol. Med. 31 (2001) 1509-1519
73. Wheeler D.S., et al. Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain. Biochem. Biophys. Res. Commun. 301 (2003) 54-59
74. Yoon H.Y., et al. TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells. Neurochem. Int. 41 (2002) 37-42
75. Cao G., et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22 (2002) 5423-5431
76. Kabouridis P.S., et al. Inhibition of NF-kappa B activity by a membrane-transducing mutant of I kappa B alpha. J. Immunol. 169 (2002) 2587-2593
77. Roeder G.E., et al. Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol. Appl. Biochem. 40 Pt 2 (2004) 157-165
78. Derer W., et al. A novel approach to induce cell cycle reentry in terminally differentiated muscle cells. FASEB J. 16 (2002) 132-133
79. Liu C.S., et al. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J. Gene Med. 3 (2001) 145-152
80. Phelan A., et al. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16 (1998) 440-443
81. Pooga M., et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16 (1998) 857-861
82. Jo D., et al. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 11 (2005) 892-898
83. Cochet O., et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58 (1998) 1170-1176
84. Anderson D.C., et al. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide. Biochem. Biophys. Res. Commun. 194 (1993) 876-884
85. Mie M., et al. Intracellular delivery of antibodies using TAT fusion protein A. Biochem. Biophys. Res. Commun. 310 (2003) 730-734
86. Niesner U., et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 13 (2002) 729-736